Diabetes Type 2 Clinical Trials 2022
Diabetes Type 2 studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect diabetes type 2 clinical trial in 2022.
Condition
Diabetes Type 2
Location
Distance
10 miles
50 miles
Any
Age
Search
Clinical Trials
Diabetes Type 2 Clinical Trials 2022
1
Effectiveness
1
Safety
Time-Restricted Eating
for Feeding, Time Restricted
La Jolla, CA
18+
All Sexes
Recruiting
La Jolla, CA
18+
All Sexes
This is a randomized clinical trial to assess the feasibility and efficacy of time-restricted eating (TRE) to improve glucose regulation and cardiovascular health of participants with type 2 diabetes mellitus (T2DM). Participants will be randomized into 2 groups: 1) standard of care (SOC), in which they will continue to follow their physician's treatment plan, or 2) SOC and TRE (8-10 hours eating window).
1
Effectiveness
1
Safety
PHOENIX
for Diabetes Mellitus, Type 2
Aurora, CO
18+
All Sexes
Waitlist Available
Aurora, CO
18+
All Sexes
Randomized, controlled, multicenter, pragmatic, pivotal trial with open-label extension evaluating the hypothesis that PHOENIX, an investigational digital therapeutic intended to help patients with type 2 diabetes improve their glycemic control, will lower hemoglobin A1c (HbA1c) compared to a control application added to usual care and across a broad range of patients in a real-world setting
1
Effectiveness
2
Safety
Diabetes Homeless Medication Support (D-Homes)
for Psychological Distress
Minneapolis, MN
18+
All Sexes
Phase 2
Waitlist Available
Minneapolis, MN
18+
All Sexes
This randomized pilot trial of the Diabetes Homeless Medication Support intervention vs. brief diabetes education will test the perception and feasibility of anticipated study procedures and refine randomization and blinding.
1
Effectiveness
1
Safety
Empathy In Action For Life With Diabetes.
for Diabetes Mellitus
Cedar Park, TX
18+
All Sexes
Waitlist Available
Cedar Park, TX
18+
All Sexes
Randomized controlled trial of the effectiveness in managing diabetes and improving mental health through a telephonic layperson-delivered empathy and relationship-focused program for patients at a Federally Qualified Health Center (FQHC) against usual care.
1
Effectiveness
2
Safety
Cagrilintide 2.4 Mg
for Diabetes Mellitus, Type 2
Carlinville, IL
18+
All Sexes
Phase 2
Waitlist Available
Carlinville, IL
18+
All Sexes
This study is evaluating whether a new medicine called cagrilintide works better with semaglutide than cagrilintide alone or semaglutide alone.
1
Effectiveness
1
Safety
Fit 24
for Diabetes Mellitus, Type 2
Houston, TX
< 18
All Sexes
Recruiting
Houston, TX
< 18
All Sexes
This study is evaluating whether a goal-setting intervention can improve physical activity and sleep in Hispanic adolescents with obesity.
1
Effectiveness
1
Safety
Shared Decision-making For Diabetes Prevention
for Diabetes, Gestational
Los Angeles, CA
18 - 65
Female
Recruiting
High Risk
Los Angeles, CA
18 - 65
Female
This study is evaluating whether a shared decision making approach to weight loss may help women with a history of gestational diabetes mellitus (GDM) who are at high risk of developing type 2
1
Effectiveness
1
Safety
Family Dyad Intervention
for Cardiovascular Diseases
Lexington, KY
18+
All Sexes
Recruiting
Lexington, KY
18+
All Sexes
Rural populations in the U.S. are disproportionately burdened by cardiovascular disease and type 2 diabetes. Lifestyle modification interventions are needed that support long-term engagement in risk-reducing health behaviors. This trial will study the effects of a family-focused, lifestyle intervention that is culturally tailored for use with rural Hispanic and non-Hispanic adults. If successful, this community-based intervention has significant potential for broad dissemination to reduce cardiovascular disease and type 2 diabetes health disparities in rural U.S. communities.
2
Effectiveness
3
Safety
Semaglutide
for Kidney Diseases
Live Oak, TX
18+
All Sexes
Phase 3
Recruiting
Live Oak, TX
18+
All Sexes
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys. Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance. Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine into the skin once a week. The study will last for about 1 year. Participants will have 11 visits to the clinic, and 2 phone visits. Some of the visits could be in different locations. Study staff will take blood samples at most of these visits. At 9 visits, participants will be asked to bring a sample of their first morning urine. At 4 of the visits participants will have to bring urine that they have collected over the last 24 hours. The study includes magnetic resonance imaging (MRI) scans of participants' kidneys which is a test that shows a detailed picture of organs and other parts inside the body. The scan will last for 30 minutes, and is free of radiation.
1
Effectiveness
1
Safety
On-screen Electronic Alert
for Diabetes Mellitus, Type 2
Dallas, TX
18+
All Sexes
Recruiting
Class I
Dallas, TX
18+
All Sexes
This study is evaluating whether a computer program can help doctors identify patients with type 2 diabetes who are at risk for heart failure.
1
Effectiveness
1
Safety
Community Health Navigator Program
for Chronic Kidney Diseases
Edmonton, Canada
18+
All Sexes
Recruiting
Stage III
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a patient navigation program can improve care for patients with multiple long-term health conditions.
1
Effectiveness
1
Safety
Community Health Navigator Program
for Chronic Kidney Diseases
Calgary, Canada
18+
All Sexes
Recruiting
Stage III
Calgary, Canada
18+
All Sexes
This study is evaluating whether a patient navigation program can improve care for patients with long-term health conditions.
1
Effectiveness
1
Safety
Community Health Navigator Program
for Chronic Kidney Diseases
Edmonton, Canada
18+
All Sexes
Recruiting
Stage III
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a patient navigation program can improve care for patients with long-term health conditions.
1
Effectiveness
1
Safety
Diabetes Self-management Education
for Diabetes Mellitus, Type 2
Brampton, Canada
18+
All Sexes
Waitlist Available
Brampton, Canada
18+
All Sexes
This study is evaluating whether a flash glucose monitor device can help people with type 2 diabetes control their blood sugar.
1
Effectiveness
1
Safety
Phosphatidylserine
for Diabetes Mellitus
Columbia, MO
18 - 65
All Sexes
Waitlist Available
Columbia, MO
18 - 65
All Sexes
This study is evaluating whether a dietary supplement may help improve blood flow in individuals with diabetes.
1
Effectiveness
1
Safety
Standard Insulin Administration Education
for Diabetes Mellitus, Type 2
Pittsburgh, PA
18+
All Sexes
Recruiting
Pittsburgh, PA
18+
All Sexes
This study is evaluating whether an educational phone application may help improve insulin administration for individuals with type 2 diabetes.
2
Effectiveness
3
Safety
Semaglutide
for Kidney Diseases
Coral Gables, FL
18+
All Sexes
Phase 3
Waitlist Available
Coral Gables, FL
18+
All Sexes
This study is evaluating whether a medicine may help slow the progression of chronic kidney disease in people with type 2 diabetes.
1
Effectiveness
1
Safety
Budgeting, Purchasing And Cooking Educational Intervention
for Diabetes Mellitus, Type 2
Eagle Butte, SD
18+
All Sexes
Recruiting
Eagle Butte, SD
18+
All Sexes
This study is evaluating whether a culturally-targeted healthy foods budgeting, purchasing, and cooking skills intervention aimed at improving the cardio-metabolic health of American Indians with type 2 diabetes who
1
Effectiveness
1
Safety
Goodbelly First
for Diabetes Mellitus, Type 2
Milwaukee, WI
18+
All Sexes
Recruiting
Milwaukee, WI
18+
All Sexes
Researchers at MCW have discovered a new pathway that links the type of bacteria present in the intestines to the severity of heart attacks. This discovery of a relationship between intestinal bacteria, bacterial metabolites, and severity of heart attacks means that for the first time, the investigators may be able to determine a person's probability of having a heart attack via non-conventional risk factors. This may provide opportunities for novel diagnostic tests as well as a potential for therapeutic intervention. The link between gut microbiota and the severity of heart attacks may also lead to novel therapeutic approaches (probiotics, non-absorbable antibiotics) to prevent heart attacks from happening. The studies proposed will test the hypothesis that altered intestinal microbiota are mechanistically linked to the pathogenesis of cardiovascular disease. The investigator's objective is to determine whether inflammatory markers in the blood are decreased and endothelial cell function improved by a probiotic in patients with established coronary artery disease. Furthermore, the investigators wish to elucidate a mechanism by which the gut microbiota regulates serum inflammatory markers. Specific Aim 1 will determine the impact of a probiotic on circulating leptin and TMAO levels, conventional risk factors for cardiovascular disease and diabetes (total cholesterol, LDL cholesterol, oxidized LDL, triglycerides, C-reactive protein, serum amyloid A, fibrinogen and adiponectin, glucose-dependent- insulinotropic polypeptide (GIP), glucagon-like-peptide (GLP-1), glucagon, insulin), and their relationship to the intestinal microbiota (15 representative microbial groups) as non conventional risk factors. Several blood samples will be collected to measure biomarkers. Participants will provide periodic stool samples in order to measure gut bacterial biodiversity. Lastly, endothelial cell function (flow mediated dilation) will be measured in order to assess blood vessel function. Specific Aim 2 will determine the impact of a probiotic on metabolites derived from the intestinal microbiota as candidates for non-conventional risk factors of cardiovascular disease. The relationship between metabolites derived from the intestinal microbiota, endothelial cell function and risk factors for cardiovascular disease identified in Specific Aim 1 will be correlated.
1
Effectiveness
1
Safety
ENCOMPASS Intervention
for Chronic Kidney Diseases
Calgary, Canada
18+
All Sexes
Recruiting
Stage III
Calgary, Canada
18+
All Sexes
This study is evaluating whether a patient navigation program can improve care for patients with chronic diseases.
1
Effectiveness
1
Safety
Dulaglutide
for Diabetes Mellitus
South Miami, FL
18+
All Sexes
Phase 1
Recruiting
South Miami, FL
18+
All Sexes
The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 when administered alone or in combination with glucagon-like peptide 1 (GLP-1) receptor agonist (RA) in participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to approximately 16 weeks excluding the screening period for each participant and include up to 17 visits.
1
Effectiveness
1
Safety
Cecelia Health Plus OneTouch Verio Reflect® BGM And OneTouch Reveal® Mobile App
for Diabetes Mellitus
San Mateo, CA
18+
All Sexes
Waitlist Available
Locally Advanced
San Mateo, CA
18+
All Sexes
ECLIPSE will evaluate the clinical and economic value of OneTouch Solutions in a real world study design. OneTouch Solutions describes a selection of devices and health and wellness solutions that people with diabetes (PWDs) can access online via OneTouch Solutions (Cecelia Health, Fitbit, Noom or Welldoc, each in combination with OneTouch Verio Reflect® blood glucose meter and the OneTouch Reveal® mobile app (or Welldoc app for the Welldoc arm)). ECLIPSE is a large parallel arm digital health study combining advanced blood glucose monitoring solutions with a choice of four different health and wellness applications or services. There are four unique study arms that will run in parallel over one year. The primary (A1c) endpoint for each study arm will be after 6 months and subjects will continue to use the interventions for a full year to generate data on sustained engagement with these products and services, and to collect healthcare utilization and health insurance claims information. Each study arm will differ to some degree in terms of patient baseline demographics (since subjects self-select their own app/intervention) and the experience per arm will be unique, and therefore each study arm will be analysed separately in terms of endpoints and outcomes.
1
Effectiveness
1
Safety
Diabetes Self-management Coaching
for Diabetes Mellitus, Type 2
Kingston, Canada
18 - 65
All Sexes
Waitlist Available
Kingston, Canada
18 - 65
All Sexes
Background: Diabetes mellitus is the third most prevalent chronic disease globally. It is a metabolic disorder characterized by elevated blood glucose because of impaired insulin production, reduced insulin effectiveness, or both. It is a major contributor for physical disability and impaired quality of life. Diabetic Self-Management programs help to control blood glucose, reduce hospitalization, and increase compliance; however, the program is underutilized in the Primary Care settings globally, due to cognitive, financial, behavioral, and emotional factors. Health coaching is a client-centered self-management approach informed by behavioral change theories to empower individuals to identify their strengths and resources and achieve their health and wellness goals. Purpose: The study's overarching goal is to determine whether implementing Diabetes Self-Management (DSM) Coaching program can be effective and feasible for individuals with type diabetes in the Ethiopian primary care context. The study has two aims: Aim 1. To determine the feasibility of implementing the Diabetic Self-Management Coaching Program Aim 2. To evaluate the effectiveness of the Diabetic Self-Management Coaching program. Method: The study will employ a single-blinded feasibility randomized controlled trial followed by a concurrent mixed-method design. A block randomization technique with block size of 4 will be used to allocate eligible participants for the quantitative part. Structured outcome measures will be used to collect data on self-efficacy, self-care practice, and glycated hemoglobin A1c. Qualitative description approach with an in-depth interview method of data collection will be used to explore perspectives of participants, barriers and facilitators, and acceptability of the program. Mean, median and frequencies will be computed. Depending on the normality of the distribution and number of participants t-test, x2 test, sign tests, and ANOVA will be considered to analyze the data. Inductive qualitative content analysis approach will be followed to analyze qualitative data. Qualitative and quantitative data will be merged at result level for further interpretation and presented in discussion section. Significance: The study will be used to determine the feasibility of the Diabetic Self-Management Coaching program in the Ethiopian primary care settings. Study participants will be benefited from the coaching program and will improve their self-efficacy, diabetes self-care practice, and blood glucose level. Furthermore, the study will have a paramount advantage to establish a foundation for future definitive trial that can prove effectiveness of the program.
1
Effectiveness
1
Safety
GZR-18
for Diabetes Mellitus, Type 2
Lincoln, NE
18 - 65
Male
Phase 1
Recruiting
Lincoln, NE
18 - 65
Male
Single ascending dose first time in human study for GZR18 in healthy subjects
2
Effectiveness
3
Safety
Semaglutide 1 Mg
for Diabetes Mellitus, Type 2
Toronto, Canada
18+
All Sexes
Phase 3
Recruiting
Toronto, Canada
18+
All Sexes
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to semaglutide. Participants will either get IcoSema or semaglutide. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe semaglutide in many countries. Participants will get IcoSema or semaglutide, which they must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will have 18 clinic visits, 34 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls. At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
1
Effectiveness
1
Safety
SomaSignal Informed Medical Management SSCVD
for Diabetes Mellitus
Atlanta, GA
18+
All Sexes
Recruiting
High Risk
Atlanta, GA
18+
All Sexes
Despite the development of novel treatments, cardiovascular disease (CVD) remains the leading cause of death and disability. It has been observed in clinical practice, that the use of novel glycemia-lowering therapies with cardioprotective features remains profoundly low despite proven efficacy. It has been proposed that such low uptake is more related to insurance type and coverage than to risk assessment. While it can be easy to blame prescribing deficiencies on complacent physicians and/or over-frugal payors, SomaLogic believes there is more likely to be a fundamental problem with the cost and risk-effective allocation of such therapies, which are neither low in cost nor free of adverse events. As current clinical trials and guidelines tend to "bundle" participants together, there is an absence of individualized assessment of residual cardiovascular risk. This leads to physicians, participants, and payors being relatively uninformed as to the need for and/or likely benefits of such therapies in an individual. Simply giving every eligible participant a drug regardless of residual risk would be unaffordable and would create adverse effects and costs for people at low residual risk who might not actually benefit from the drugs. To resolve this lack of precision in risk assessment, SomaLogic has performed the largest ever proteomic program to date with over 36,000 samples from 26,000 participants in eleven clinical studies, for a total of over 180,000,000 protein measurements, to develop and validate a surrogate proteomic endpoint for cardiovascular outcomes. The SomaSignal Cardiovascular Risk (SSCVR) test, a 27-protein model encompassing ten biological systems.
1
Effectiveness
1
Safety
Normal Saline
for Diabetes Mellitus
Nashville, TN
18 - 65
All Sexes
Phase 1
Waitlist Available
Nashville, TN
18 - 65
All Sexes
This study aims to assess the effect and breakdown of lysine administration, specifically examining whether it leads to increased plasma 2-AAA in healthy humans.
3
Effectiveness
3
Safety
Dapagliflozin
for Diabetes Mellitus
Boston, MA
18+
All Sexes
Phase 4
Recruiting
Boston, MA
18+
All Sexes
Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can lead to a higher chance of developing heart attacks or strokes. New medications for T2DM including dapagliflozin, which is a Sodium-Glucose Cotransporter-2 inhibitor (SGLT2) inhibitor, may help protect the heart and blood vessels. The overarching objective of this mechanistic study is to learn how a Sodium-Glucose Cotransporter-2 (SGT2) inhibitor, dapagliflozin, impacts vascular health in patients with Type 2 Diabetes Mellitus (T2DM). The investigators will compare the changes in vascular health to changes in endothelial cell (EC) phenotype including non-coding RNA (ncRNA) to develop evidence supporting the mechanism of cardiovascular benefit of SGLT2 inhibitors. This study will provide novel information regarding the mechanism of effects of novel treatments for endothelial function and vascular health in patients with T2DM to reduce cardiovascular (CV) risk. The research aims to assess the: effects of dapagliflozin on EC phenotype. impact of dapagliflozin on vasodilator function and additional measures of vascular health including arterial stiffness and circulating markers of vascular health.
1
Effectiveness
2
Safety
Insulin Detemir
for Diabetes, Gestational
Los Angeles, CA
18+
All Sexes
Phase 2
Recruiting
Los Angeles, CA
18+
All Sexes
The purpose of the study is to compare rates of neonatal hypoglycemia with maternal NPH vs determir use.
1
Effectiveness
1
Safety
Case-management
for Diabetes Mellitus, Type 2
Martinez, CA
18+
All Sexes
Recruiting
Martinez, CA
18+
All Sexes
This study is evaluating whether a nutrition program can improve diabetes control in people with diabetes.
1
Effectiveness
1
Safety
ELG
for Diabetes Mellitus
Springdale, AR
18+
All Sexes
Waitlist Available
Springdale, AR
18+
All Sexes
This study is evaluating whether a new device can measure blood glucose levels without taking blood samples.
2
Effectiveness
3
Safety
Afrezza
for Diabetes, Autoimmune
Orange, CA
< 18
All Sexes
Phase 3
Recruiting
Orange, CA
< 18
All Sexes
This study is evaluating whether Afrezza is safe and effective in combination with a basal insulin in pediatric subjects with type 1 or type 2 diabetes mellitus.
1
Effectiveness
2
Safety
Zanamivir
for Diabetes Mellitus
Columbia, MO
18 - 65
All Sexes
Phase 2
Recruiting
Columbia, MO
18 - 65
All Sexes
This study is evaluating whether a drug that inhibits neuraminidase can improve endothelial function in people with type 2 diabetes.
1
Effectiveness
1
Safety
Type 2 Diabetes Appropriate Food Boxes + Diabetes Education
for Diabetes Mellitus, Type 2
Fayetteville, AR
18+
All Sexes
Recruiting
Fayetteville, AR
18+
All Sexes
Develop, implement, and evaluate the effectiveness of an intervention to use home-delivery of Type 2 diabetes (T2D)-appropriate food boxes with plain language adapted education materials to improve the nutritional health, physical activity, and health outcomes of low-income food insecure people with T2D in northwest Arkansas.
1
Effectiveness
1
Safety
MTM
for Diabetes Mellitus, Type 2
Chapel Hill, NC
18+
All Sexes
Recruiting
Chapel Hill, NC
18+
All Sexes
This study is evaluating whether a medically tailored meal program may help improve diabetes management for individuals with food insecurity.
1
Effectiveness
1
Safety
Healthy Food Subsidy
for Diabetes Mellitus, Type 2
Multiple Locations, Canada
18+
All Sexes
Recruiting
Multiple Locations, Canada
18+
All Sexes
This study is evaluating whether a subsidized healthy food prescription program can improve blood glucose levels in people with diabetes.
2
Effectiveness
3
Safety
Oral Semaglutide
for Diabetes Mellitus, Type 2
Calgary, Canada
18+
All Sexes
Phase 3
Waitlist Available
Calgary, Canada
18+
All Sexes
This study is evaluating whether a drug may help treat type 2 diabetes.
2
Effectiveness
3
Safety
Insulin Icodec
for Diabetes Mellitus, Type 2
Chicago, IL
18+
All Sexes
Phase 3
Waitlist Available
Chicago, IL
18+
All Sexes
This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. Participants will either get insulin icodec that participants will have to inject once a week on the same day of the week or insulin glargine that participants will have to inject once a day at the same time every day. Which treatment participants get is decided by chance. The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach. The study will last for about 1 ½ years. Participants will have 37 clinic visits and 26 phone calls with the study doctor. At 11 clinic visits participant will have blood samples taken. At 8 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Participants will be asked to wear a sensor that measures the blood sugar all the time in 5 periods of about one month during the study (about 5 months in total). Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
1
Effectiveness
1
Safety
Family Diabetes Self-Management Education And Support
for Diabetes Mellitus, Type 2
Fayetteville, AR
18+
All Sexes
Recruiting
Fayetteville, AR
18+
All Sexes
This study is evaluating whether family involvement in diabetes education sessions will improve outcomes for patients with type 2 diabetes.
3
Effectiveness
3
Safety
Ertugliflozin 5 Mg
for Diabetes Mellitus
Cleveland, OH
18+
All Sexes
Phase 4
Recruiting
Cleveland, OH
18+
All Sexes
This clinical trial will determine if subjects with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM2) receiving sodium-glucose cotransporter 2 (SGLTi2) inhibitor therapy (ertugliflozin) alters cardiac metabolism compared to placebo in a single blinded (to subject), randomized, parallel group, active controlled, single center experimental design.
1
Effectiveness
1
Safety
Autologous Adipose-derived Mesenchymal Stem/stromal Cells (MSC) Higher Dose
for Diabetes Mellitus, Type 2
Rochester, MN
18+
All Sexes
Phase 1
Recruiting
Rochester, MN
18+
All Sexes
This study is evaluating whether stem cells from fat may help treat kidney disease.
1
Effectiveness
1
Safety
Tailored Lighting Intervention
for Alzheimer Disease
New York, NY
18+
All Sexes
Recruiting
New York, NY
18+
All Sexes
This study is evaluating whether a lighting intervention may help treat Alzheimer's disease.
1
Effectiveness
1
Safety
Peer Led Diabetes Self-Management Support
for Diabetes Mellitus
Ann Arbor, MI
18+
Male
Recruiting
Ann Arbor, MI
18+
Male
The Michigan Men's Diabetes Project 2 (MenD 2) is an 18-month pilot randomized clinical trial. We are looking to recruit 60 Black men with type 2 diabetes (need to have diagnosis for at least 6 months) that are over the age of 21. Interested participants need to be under the care of a physician for their diabetes, have access to reliable transportation for study activities, and be willing to participate in 4 health assessments where they will get their A1C, blood pressure, height, and weight measured and they will complete a survey. All participants will receive 10 hours of diabetes self-management education with a Certified Diabetes Care and Education Specialist. Participants randomized to the intervention arm will also be offered 6 months of monthly diabetes self-management support (DSMS) sessions with trained Peer Leaders who are also Black men with type 2 diabetes. After the 6 months of support, this group will transition into 6 months of ongoing support where they can continue DSMS and/or other diabetes related initiatives that are important to the group and chosen by the group. Due to the COVID-19 pandemic, DSME and DSMS sessions will likely be held via Zoom, ongoing support sessions have potential to be in person. The 4 health assessments will take place at baseline, 3-months, 9-months, and 15-months.
2
Effectiveness
3
Safety
IcoSema
for Diabetes Mellitus
Greensboro, NC
Any Age
All Sexes
Phase 3
Recruiting
Greensboro, NC
Any Age
All Sexes
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec. Participants will either get IcoSema or insulin icodec. Which treatment participants get is decided by chance. IcoSema and insulin icodec are both new medicines that doctors cannot prescribe. Participants will get IcoSema or insulin icodec, which participants must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will have 21 clinic visits, 31 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period. Not applicable for China: Participants will be asked to wear a sensor that measures their blood sugar level all the time during a 5 week period at the end of the study.
1
Effectiveness
1
Safety
Diabetes Education
for Diabetes Mellitus
Milwaukee, WI
18+
All Sexes
Waitlist Available
Milwaukee, WI
18+
All Sexes
The overarching aim of this proposal is to test the efficacy of financial incentives in improving HbA1c, blood pressure, and quality of life in food insecure adults with poorly controlled type 2 diabetes. Using a clinical trial design, the investigators will randomize food insecure adults with type 2 diabetes to one of three financial incentive structures in combination with monthly mailings that will include diabetes education, healthy recipes, and meal planning resources.
2
Effectiveness
3
Safety
Tirzepatide Dose 2
for Type2 Diabetes
Aurora, CO
< 65
All Sexes
Phase 3
Recruiting
Aurora, CO
< 65
All Sexes
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both. The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic visits will include blood sample collection, physical exam and questionnaire.
1
Effectiveness
1
Safety
Exogenous Ketone Monoester
for Diabetes Mellitus
Kelowna, Canada
18+
All Sexes
Recruiting
Kelowna, Canada
18+
All Sexes
Ketone bodies are a fuel source and signaling molecule that are produced by the body during prolonged fasting or if an individuals consistently eats a low-carbohydrate "keto" diet. Blood ketones can be used as a source of energy by the body, but they may also act as signals that impact the functioning of different cells in the body. Recently, the availability of ketone supplements that can be taken orally allows for raising blood ketones without having to fast or eat a "keto" diet. The investigators' studies and those of other researchers have shown that ketone supplementation can lower blood sugar without having to make any other dietary changes. Oral ingestion of ketones may therefore be an effective strategy to improve blood sugar control and influence how cells function. The main objective of this study is to determine if consuming a ketone supplement 3 times per day (before meals) for 14 days lowers blood sugar and impacts how the body's cells function. The results of this study will be used to guide future recommendations on the utility of ketone supplements for improving health in individuals with, or at elevated risk of, type 2 diabetes.
1
Effectiveness
1
Safety
Noom Mobile Application
for Diabetes Mellitus
New Brunswick, NJ
18+
All Sexes
Recruiting
New Brunswick, NJ
18+
All Sexes
This study is evaluating whether a smartphone app can help people with type 2 diabetes lose weight.
1
Effectiveness
1
Safety
MANUP
for Coping Behavior
Durham, NC
18+
Male
Recruiting
Durham, NC
18+
Male
Many Black Americans continue to be suffer from diabetes especially Black men. Although previous diabetes efforts have reduced overall disease burden, they have failed to eliminate racial and geographic disparities. The story of John Henry, the "steel-drivin' man" represents strength and self-determination among Black Men. But often these traits lead men to "manup" about their health and prevents them from taking care of their diabetes. This study examines how we can assist Black men in improving their diabetes. Based on the traits of John Henry, we will conduct a culturally-tailored study to 1) determine if our education program including coping strategies and motivation text messages lowers A1c; and, 2) how program operates in a rural setting while learning how we can best improve it for a larger study. We hope to have the information to conduct a larger study with Black men in rural areas to improve their diabetes outcomes.
3
Effectiveness
3
Safety
Semaglutide
for Diabetes Mellitus, Type 2
La Jolla, CA
18+
All Sexes
Phase 4
Recruiting
La Jolla, CA
18+
All Sexes
This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. The purpose of the
1
Effectiveness
1
Safety
MTM + ILI
for Diabetes Mellitus, Type 2
Chapel Hill, NC
18+
All Sexes
Recruiting
Chapel Hill, NC
18+
All Sexes
This study is evaluating whether a medically tailored meal + intensive lifestyle intervention can improve health outcomes for people with diabetes and food insecurity.
1
Effectiveness
1
Safety
Office Guidelines Applied To Practice (Office-GAP) + Mobile Text Messaging
for Diabetes Mellitus, Type 2
Lansing, MI
18+
All Sexes
Recruiting
Lansing, MI
18+
All Sexes
Cardiovascular disease (CVD) complications are the leading cause of diabetes mellitus (DM)-related morbidity and mortality, creating a significant burden on the public health system. This burden is, in part, attributable to poor medication adherence, with 21-42% of patients failing to properly adhere to their care. Importantly, this issue is especially pronounced in minority and low-income populations, which show higher rates of chronic illness and lower medication adherence. Interventions that foster and reinforce patient-centered communication between clinicians and patients show promise in improving health outcomes. However, they have not been widely implemented, in part due to a lack of compelling evidence for their effectiveness in primary care settings. Project Objective: The investigators propose to evaluate the impact of a patient activation program: Office Guidelines Applied to Practice (Office-GAP) combined with mobile text messaging reinforcement (Way to Health [W2H]) on medication adherence in patients with DM compared to mobile texting alone. Office-GAP incorporates shared decision-making and a decision/support checklist to be completed during office visits, to foster patients' investment in their own care. W2H is a texting service that informs and encourages patients to adhere to goals and improve communication. The long-term goal is to develop a model that can reliably improve and sustain adherence and can be successfully implemented in primary care clinics to close the morbidity and mortality gap for minority/low-income DM patients. The hypothesis is that the combined face-to-face patient activation and texting- delivered reinforcement methods will facilitate communication between patients and providers, improving the frequency, accuracy, and timeliness of communication while reinforcing shared goals and engendering mutual respect more than texting alone. Improved communication between patients and providers may improve medication adherence, blood sugar, cholesterol, blood pressure control, and patient satisfaction with providers, and ultimately decrease burden of illness. Research Strategy: The investigators will conduct a randomized community-based clinical trial in Federally-Qualified Health Centers (FQHCs) in Michigan enrolling 378 patients in 17 teams. All patients will receive usual care and medication for DM and CVD prevention. Eight teams will use W2H alone, and 9 teams will combine Office-GAP with WTH. The investigators will evaluate the impact of shared decision-making strategies for patients and providers. Impact: If successfully translated to clinical practice, these interventions have the potential to significantly impact patient care in FQHCs, improving outcomes for DM and CVD. This research also paves the way for shifting clinical practice across a spectrum of chronic disease where medication non-adherence is an issue.
1
Effectiveness
1
Safety
Allogeneic Adipose-derived Mesenchymal Stem Cells (MSC)-Single Infusion
for Kidney Diseases
Jacksonville, FL
18+
All Sexes
Phase 1
Recruiting
Jacksonville, FL
18+
All Sexes
This study is evaluating whether a type of white blood cell called mesenchymal stem cells may help treat chronic kidney disease.
1
Effectiveness
2
Safety
ORMD-0801 (Insulin) Capsule 8 Mg BD
for Diabetes Mellitus, Type 2
Tustin, CA
18+
All Sexes
Phase 2
Waitlist Available
Tustin, CA
18+
All Sexes
This study is evaluating whether a new insulin pill may help treat type 2 diabetes and NASH.
1
Effectiveness
2
Safety
Dexcom G6 Professional Continuous Glucose Monitor
for Premature Birth
Birmingham, AL
< 65
All Sexes
Phase 2
Recruiting
Birmingham, AL
< 65
All Sexes
This study is evaluating whether a set of activities can improve sleep habits in people with dementia.
3
Effectiveness
3
Safety
Ticagrelor Monotherapy
for Diabetes Mellitus
Jacksonville, FL
18+
All Sexes
Phase 4
Recruiting
High Risk
Jacksonville, FL
18+
All Sexes
This study is evaluating whether a drug called ticagrelor may be able to help reduce the risk of heart attacks and strokes in patients with coronary artery disease.
1
Effectiveness
1
Safety
High Carbohydrate (glycogen Loading)
for Diabetes Mellitus, Type 2
Charlottesville, VA
18+
All Sexes
Recruiting
Charlottesville, VA
18+
All Sexes
This study is evaluating whether glycogen content in the liver may play a role in regulating glucose production.
2
Effectiveness
3
Safety
Semaglutide
for Diabetes Mellitus, Type 2
Asheville, NC
18+
All Sexes
Phase 3
Recruiting
Asheville, NC
18+
All Sexes
This study is evaluating whether a medicine may help prevent vision loss in people with diabetes.
1
Effectiveness
1
Safety
High-Fruit Diet
for Diabetes Mellitus, Type 2
Birmingham, AL
18+
All Sexes
Recruiting
Birmingham, AL
18+
All Sexes
Diabetes costs the U.S. healthcare system more than any other disease, and nearly half of Americans will develop either diabetes or prediabetes in their lifetime. It is therefore critical to find new strategies to treat or reverse diabetes. One such approach is adopting a healthy diet, which can dramatically improve blood sugar levels in adults with type 2 diabetes and even induce diabetes remission. Despite this, not much is known about which food groups are most effective at improving blood sugar levels in patients with diabetes. Interestingly, of the various food groups that comprise the Mediterranean diet, epidemiologic data suggests that whole fruit may be one of the most efficacious at both preventing type 2 diabetes and improving blood sugar in patients with type 2 diabetes. However, few clinical trials have investigated the effects of whole fruit on blood sugar control. This study will therefore be the first to determine the effects of increasing whole fruit as a food group in type 2 diabetes patients. This supervised controlled feeding trial will test whether consuming a diet rich in whole fruit for 12 weeks can induce diabetes remission and can improve blood sugar, liver fat, and cardiovascular health in adults with type 2 diabetes. Thereafter, participants will be followed for up to one year. As a secondary aim, this study will also test whether consuming a large amount of fructose in whole food form negatively affects liver fat and cardiovascular health.
1
Effectiveness
1
Safety
Socially-Based Exercise Intervention For Older Adults
for Sarcopenia
Scotts Hill, TN
18+
All Sexes
Recruiting
Scotts Hill, TN
18+
All Sexes
This study is evaluating whether a mobile application may help improve the health of older adults.
1
Effectiveness
2
Safety
18F-MK6240 Injection
for Prediabetic State
New York, NY
18+
All Sexes
Phase 2
Waitlist Available
New York, NY
18+
All Sexes
This study is evaluating whether diabetes and glycemia are related to brain tau accumulation.
2
Effectiveness
3
Safety
Canagliflozin 300 Mg
for Diabetes Mellitus, Type 2
Philadelphia, PA
< 18
All Sexes
Phase 3
Recruiting
Philadelphia, PA
< 18
All Sexes
This study is evaluating whether a drug may help lower blood sugar levels in people with type 2 diabetes.
3
Effectiveness
3
Safety
Dapagliflozin
for Diabetes Mellitus, Type 2
San Antonio, TX
18+
All Sexes
Phase 4
Waitlist Available
Newly Diagnosed
San Antonio, TX
18+
All Sexes
This study is evaluating whether a drug used to treat type 2 diabetes may help reduce kidney damage in type 1 diabetes.
1
Effectiveness
1
Safety
Technology Intensified
for Diabetes Mellitus, Type 2
Charleston, SC
18+
All Sexes
Waitlist Available
Charleston, SC
18+
All Sexes
This study is evaluating whether a technology-based intervention can help people with diabetes.
1
Effectiveness
1
Safety
Avocado Vouchers
for Dietary Habits
Santa Barbara, CA
18+
All Sexes
Recruiting
Santa Barbara, CA
18+
All Sexes
Hispanic/Latino adults in the United States (U.S.) bear a disproportionate burden of type 2 diabetes (T2D). Dietary changes, facilitated by increased access and adherence to healthy foods, are necessary. In this study, continuous glucose monitoring (CGM) will be used to quantify changes in glycemic control in Hispanic/Latino (predominantly of Mexican origin) adults with or at-risk of T2D before and after receiving free avocados for 12 weeks. Beyond CGM-measured glycemic control, wearable activity and sleep monitors, physical exams, laboratory analyses, and questionnaires/logs will be used to track the impact of free avocado vouchers. The findings are anticipated to help clinicians provide new information to support positive behavior change to reduce the risk of T2D or progression from pre-diabetes to T2D and make it easier for patients to access healthier food, potentially leading to improved health.
1
Effectiveness
1
Safety
Hot Water
for Diabetes Mellitus
Montréal, Canada
18+
All Sexes
Recruiting
Montréal, Canada
18+
All Sexes
Insulin resistance and hyperglycemia predispose individuals with type 2 diabetes mellitus (T2DM) to endothelial dysfunction and a greater risk of cardiovascular diseases (CVD). Increased CVD risk in individuals with T2DM persists despite optimal pharmacological therapy, highlighting the need to identify complementary lifestyle interventions that improve cardiometabolic functions in this population. Evidence from animal models suggests that heat exposure improves metabolic functions. Notably, weekly heat exposure for 16 weeks blunts hyperinsulinemia and hyperglycemia induced by a high fat diet in mice. In parallel, studies in humans have shown that heat exposure improves vascular endothelial function. Based on such findings, it has been suggested that heat therapy may represent an effective lifestyle intervention to improve cardiometabolic functions. However, only 1 study has examined the impact of a heat therapy intervention on individuals with T2DM, demonstrating that 6 weeks of heat exposure reduces fasting plasma glucose and hemoglobin A1C. No study has considered potential vascular benefits of heat therapy in individuals with T2DM. This project will investigate cardiometabolic responses to repeated heat exposure in men and women with T2DM. We will test the hypothesis that 12 weeks of heat therapy improves postprandial fatty acid handling, insulin sensitivity and endothelial function in individuals with T2DM.
1
Effectiveness
1
Safety
Use Of Patient Portal For Diabetes Management
for Education, Patient
Norwalk, CT
18+
All Sexes
Waitlist Available
Norwalk, CT
18+
All Sexes
The purpose of the study is to develop and evaluate a multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
1
Effectiveness
2
Safety
Semaglutide
for Diabetes Mellitus, Type 2
Lake Charles, LA
18+
All Sexes
Phase 2
Recruiting
Lake Charles, LA
18+
All Sexes
This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes. The study is being conducted to see how well semaglutide, in combination with different doses of NNC0480-0389, work to lower blood sugar levels. Results from this study will be used to select the doses of the two medicines for other studies. Participants will either get: Semaglutide (a medicine doctors can already prescribe for treatment of type 2 diabetes) in combination with NNC0480-0389 (a potential new medicine) or placebo (a 'dummy' medicine that looks like the medicines but without any medicine). NNC0480-0389 alone, or semaglutide alone which treatment participant get is decided by chance. Participant will need to take 2-3 injections once every week during the study. One injection will be with semaglutide or placebo and 1-2 injections will be with NNC0480-0389 or placebo. Participant must inject the study medicines themself into the stomach, thigh, or upper arm. The study will last for about 41weeks. Participant will have 20 clinic visits. Participant will have blood samples taken at all clinic visits. At 3 clinic visits, participant will also have an electrocardiogram (ECG). This is a test to check participants heart. Participant will have their eyes checked before or at the start of the study and at the end of the study. Women can only take part in the study if they are not able to become pregnant
1
Effectiveness
1
Safety
Meal Replacement Shake
for Diabetes Mellitus
Santa Monica, CA
18+
All Sexes
Waitlist Available
Santa Monica, CA
18+
All Sexes
This is an open-label single-arm observational trial to study the effectiveness of a commercially available meal-replacement shake and its effect on the quality of life in individuals with type 2 diabetes.
1
Effectiveness
1
Safety
Goldenseal (Hydrastis Canadensis)
for Diabetes Mellitus, Type 2
Spokane, WA
18+
All Sexes
Phase < 1
Recruiting
Spokane, WA
18+
All Sexes
This study is evaluating whether goldenseal might interact with metformin in people with diabetes.
1
Effectiveness
1
Safety
CDS Tool Access
for Diabetes Mellitus, Type 2
San Francisco, CA
18+
All Sexes
Waitlist Available
San Francisco, CA
18+
All Sexes
This study is evaluating whether providing care team members with clinical decision support tools can improve outcomes for patients with hypertension and diabetes.
2
Effectiveness
3
Safety
IcoSema
for Diabetes Mellitus
Amarillo, TX
18+
All Sexes
Phase 3
Recruiting
Amarillo, TX
18+
All Sexes
This study is evaluating whether a new medicine can control blood sugar levels in people with type 2 diabetes.